Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2006-07-14
2010-06-22
Leavitt, Maria (Department: 1633)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C424S093100, C435S091400, C435S320100, C435S325000
Reexamination Certificate
active
07740837
ABSTRACT:
The present invention relates to compositions comprising a therapeutically effective amount of genetically modified cells containing a genetic construct expressing a TGFβ inhibitor effective to reduce expression of TGFβ, where the genetically modified cells are non-small cell lung cancer (NSCLC) cells or small cell lung cancer (SCLC) cells, and related methods.
REFERENCES:
patent: 5095095 (1992-03-01), Fontana
patent: 5168062 (1992-12-01), Stinski
patent: 5385839 (1995-01-01), Stinski
patent: 5674486 (1997-10-01), Sobol et al.
patent: 5681562 (1997-10-01), Sobol et al.
patent: 5772995 (1998-06-01), Fakhrai et al.
patent: 5824655 (1998-10-01), Border
patent: 6120763 (2000-09-01), Fakhrai et al.
patent: 6447769 (2002-09-01), Fakhrai et al.
patent: 6455689 (2002-09-01), Schlingensiepen et al.
patent: 2002/0192199 (2002-12-01), Habib
patent: 2003/0040499 (2003-02-01), Sclingensiepen et al.
patent: 2003/0050265 (2003-03-01), Dean et al.
patent: 2004/0006030 (2004-01-01), Monia
patent: 2004/0063655 (2004-04-01), Dean et al.
patent: 2004/0147472 (2004-07-01), Murray et al.
patent: 0695 354 (2002-01-01), None
patent: WO 85/04421 (1985-10-01), None
patent: WO 88/03807 (1988-06-01), None
patent: WO 93/07906 (1993-04-01), None
patent: WO 94/25588 (1994-11-01), None
patent: WO 96/02143 (1996-02-01), None
patent: WO 96/25178 (1996-08-01), None
patent: WO 97/27876 (1997-08-01), None
patent: WO 01/19161 (2001-03-01), None
patent: WO 01/74404 (2001-10-01), None
patent: WO 2004/005552 (2004-01-01), None
patent: WO 2005/084712 (2005-09-01), None
Gold L. Critical Reviews in Ontogenesis, 1999, The role of transforming Growth Factor Beta (TGF), pp. 303-360.
Voskoglou-Nomikos T,et al., Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models.Clin Cancer Res. Sep. 15, 2003;9(11):4227-39.
KoheiMiyazono et al., TGF-β signaling by Smad proteins Cytokine & Growth Factor Reviews vol. 11, Issues 1-2, Apr. 2000, pp. 15-22.
Chen et al., Microsatellite alterations in plasma DNA of small cell lung cancer patients Nat Med. Sep. 1996;2(9):1033-5.
Fisher et al., 1994, Eur. J. Cancer (1994) 30A:2125-2129.
Asselin-Paturel, C. et al. 1998 “Quantitative analysis of Th1, Th2 and TGF-β1 cytokine expression in tumor, Til and PBL of non-small cell lung cancer patients.”Int. J. Cancer77: 7-12.
Fakhrai H. et al. 1996 “Eradication of established intracranial rat gliomas by transforming growth factor β antisense gene therapy.”PNAS USA93: 2909.
Fakhrai, H. et al. 2000 “Gene therapy of human gliomas with TGF-β2 antisense gene modified autologous tumor cells. A Phase I clinical trial.”Proc. Amer. Assoc. Cancer Res. Annu. Meeting41:543.
Fakhrai, H. et al., 1995 “Immunization with TGF-β2 antisense gene modified tumor cells eradicates intracranial gliomas.”Proc. Annu. Meeting of the Amer. Assoc. Cancer Res.36:463-E.
Fischer, J.R., et al. 1994 “Constitutive secretion of bioactive transforming growth factor β1by small cell lung cancer cell lines.”Eur. J. Cancer30A:2125-2129.
Goodman and Gilman's 1996 “The Pharmacological Basis of Therapeutics” Ninth Edition, McGraw-Hill, pp. 77-101.
Marshall, E. 1995 “Gene therapy's growing pains.”Science269: 1050-1055.
Norgaard, P. et al. 1996 “Expression and autoregulation of transforming growth factor β receptor mRNA in small-cell lung cancer cell lines.”Brit. J. Cancer73:1037-1043.
Ogawa, Y. et al. 1991 “Purification of transforming growth factors β1 and β2 from bovine bone and cell culture assays.”Meth. Enzymol.198: 317-327.
Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy, Dec. 1995, p. 11.
Sandhu, J.S. et al. 1997 “Human gene therapy.”Crit. Rev. Biotechnol.17:307-326.
Schwartzentruber, D.J. et al. 1993 “Tumor-infiltrating lymphocytes derived from select B-cell lymphomas secrete granulocyte-macrophage colony-stimulating factor and tumor necrosis factor-α in response to autologous tumor stimulation.”Blood82:1204-1211.
Sharma, S. et al. 1997 “Multicomponent gene therapy vaccines for lung cancer: effective eradication of established murine tumors in vivo with interleukin-7/herpes simplex thymidine kinase-transduced autologous tumor and ex vivo activated dendritic cells.”Gene Ther.4:1361-1370.
Sobol, R.E. et al. 1999 “Interleukin 2 gene therapy of colorectal carcinoma with autologous irradiated tumor cells and genetically engineered fibroblasts: a Phase I study.”Clin. Cancer. Res.5:2359-2365.
Leavitt Maria
Morrison & Foerster / LLP
Novarx
LandOfFree
Genetically modified cells expressing a TGF beta inhibitor,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Genetically modified cells expressing a TGF beta inhibitor,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Genetically modified cells expressing a TGF beta inhibitor,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4177685